Adage Capital Partners Portfolio holdings
AUM
$59.3B
This Quarter Return
+9.95%
1 Year Return
+26.26%
3 Year Return
+130.73%
5 Year Return
+248.99%
10 Year Return
+658.76%
AUM
$39.9B
AUM Growth
+$39.9B
(+2.3%)
Cap. Flow
-$403M
Cap. Flow
% of AUM
-1.01%
Top 10 Holdings %
Top 10 Hldgs %
26.01%
Holding
846
New
122
Increased
199
Reduced
390
Closed
98
Top Buys
| 1 |
Apple
AAPL
|
$1.55B |
| 2 |
Johnson & Johnson
JNJ
|
$172M |
| 3 |
Sensata Technologies
ST
|
$154M |
| 4 |
Bristol-Myers Squibb
BMY
|
$134M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
$102M |
Top Sells
| 1 |
Otis Worldwide
OTIS
|
$167M |
| 2 |
Ross Stores
ROST
|
$115M |
| 3 |
Five Below
FIVE
|
$100M |
| 4 |
Freeport-McMoran
FCX
|
$100M |
| 5 |
Fortune Brands Innovations
FBIN
|
$95.4M |
Sector Composition
| 1 | Technology | 23.11% |
| 2 | Healthcare | 19.47% |
| 3 | Consumer Discretionary | 12.59% |
| 4 | Financials | 11.28% |
| 5 | Communication Services | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Jabil
JBL
$22B
| $50.6M | 0.13% | 1,477,086 -232,712 | -14% | -$7.97M |
|
177
Biogen
BIIB
$19.4B
| $50.2M | 0.13% | 176,880 +121,290 | +218% | +$34.4M |
|
178
Comerica
CMA
$9.07B
| $50.2M | 0.13% | 1,311,212 +174,296 | +15% | +$6.67M |
|
179
CACI
CACI
$10.6B
| $50M | 0.13% | 234,787 +179,787 | +327% | +$38.3M |
|
180
Eli Lilly
LLY
$657B
| $49.4M | 0.12% | 333,851 +121,200 | +57% | +$17.9M |
|
181
Protagonist Therapeutics
PTGX
$3.67B
| $49.3M | 0.12% | 2,520,600 +320,600 | +15% | +$6.27M |
|
182
Republic Services
RSG
$73B
| $49.2M | 0.12% | 526,570 +80,137 | +18% | +$7.48M |
|
183
Interpublic Group of Companies
IPG
$9.83B
| $48M | 0.12% | 2,882,340 +2,481,569 | +619% | +$41.4M |
|
184
Hartford Financial Services
HIG
$37.2B
| $47.7M | 0.12% | 1,294,483 +407,000 | +46% | +$15M |
|
185
Karyopharm Therapeutics
KPTI
$61.7M
| $46.9M | 0.12% | 3,212,931 -35,808 | -1% | -$523K |
|
186
US Bancorp
USB
$76B
| $46.8M | 0.12% | 1,304,100 -129,700 | -9% | -$4.65M |
|
187
Northrop Grumman
NOC
$84.5B
| $46.5M | 0.12% | 147,243 +72,017 | +96% | +$22.7M |
|
188
Garmin
GRMN
$46.5B
| $46.4M | 0.12% | 489,012 -57,107 | -10% | -$5.42M |
|
189
Pinnacle West Capital
PNW
$10.7B
| $46.3M | 0.12% | 621,063 +96,000 | +18% | +$7.16M |
|
190
Kura Oncology
KURA
$686M
| $46M | 0.12% | 1,500,450 -309,000 | -17% | -$9.47M |
|
191
Immunovant
IMVT
$2.56B
| $45.9M | 0.12% | 1,305,000 -1,061,062 | -45% | -$37.3M |
|
192
DuPont de Nemours
DD
$32.2B
| $45.5M | 0.11% | 819,855 -31,600 | -4% | -$1.75M |
|
193
Schlumberger
SLB
$55B
| $45.5M | 0.11% | 2,922,867 +962,800 | +49% | +$15M |
|
194
Baxter International
BAX
$12.7B
| $45.4M | 0.11% | 564,252 -465,100 | -45% | -$37.4M |
|
195
Cameco
CCJ
$33.7B
| $45.3M | 0.11% | 4,486,089 -4,250,000 | -49% | -$42.9M |
|
196
Parker-Hannifin
PH
$96.2B
| $45.2M | 0.11% | +223,420 | New | +$45.2M |
|
197
Gen Digital
GEN
$18.6B
| $45.1M | 0.11% | 2,166,216 +28,600 | +1% | +$596K |
|
|
FLG
198
Flagstar Financial, Inc.
FLG
$5.33B
| $45M | 0.11% | 5,444,893 +2,184,295 | +67% | +$18.1M |
|
199
Olin
OLN
$2.71B
| $44.8M | 0.11% | 3,619,782 -2,200,000 | -38% | -$27.2M |
|
200
DexCom
DXCM
$29.5B
| $44.2M | 0.11% | 107,169 +400 | +0.4% | +$165K |
|